A randomized trial of factor VIII and neutralizing antibodies in hemophilia A

F. Peyvandi; P. M. Mannucci; I. Garagiola; A. El-Beshlawy; M. Elalfy; V. Ramanan; P. Eshghi; S. Hanagavadi; R. Varadarajan; M. Karimi; M. V. Manglani; C. Ross; G. Young; T. Seth; S. Apte; D. M. Nayak; E. Santagostino; M. E. Mancuso; A. C. Sandoval Gonzalez; J. N. Mahlangu; S. Bonanad Boix; M. Cerqueira; N. P. Ewing; C. Male; T. Owaidah; Soto V. Arellano; N. L. Kobrinsky; S. Majumdar; R. Perez Garrido; A. Sachdeva; M. Simpson; M. Thomas; E. Zanon; B. Antmen; K. Kavakli; M. J. Manco-Johnson; M. Martinez; E. Marzouka; M. G. Mazzucconi; D. Neme; A. Palomo Bravo; R. Paredes Aguilera; A. Prezotti; K. Schmitt; B. M. Wicklund; B. Zulfikar; F. R. Rosendaal

doi:10.1056/NEJMoa1516437

A randomized trial of factor VIII and neutralizing antibodies in hemophilia A

F. Peyvandi, P. M. Mannucci, I. Garagiola, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S. Hanagavadi, R. Varadarajan, M. Karimi, M. V. Manglani, C. Ross, G. Young, T. Seth, S. Apte, D. M. Nayak, E. Santagostino, M. E. Mancuso, A. C. Sandoval Gonzalez, J. N. MahlanguS. Bonanad Boix, M. Cerqueira, N. P. Ewing, C. Male, T. Owaidah, Soto V. Arellano, N. L. Kobrinsky, S. Majumdar, R. Perez Garrido, A. Sachdeva, M. Simpson, M. Thomas, E. Zanon, B. Antmen, K. Kavakli, M. J. Manco-Johnson, M. Martinez, E. Marzouka, M. G. Mazzucconi, D. Neme, A. Palomo Bravo, R. Paredes Aguilera, A. Prezotti, K. Schmitt, B. M. Wicklund, B. Zulfikar, F. R. Rosendaal

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age

Original language	English
Pages (from-to)	2054-2064
Number of pages	11
Journal	New England Journal of Medicine
Volume	374
Issue number	21
DOIs	https://doi.org/10.1056/NEJMoa1516437
Publication status	Published - May 26 2016

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJMoa1516437

Fingerprint Dive into the research topics of 'A randomized trial of factor VIII and neutralizing antibodies in hemophilia A'. Together they form a unique fingerprint.

Cite this

Peyvandi, F., Mannucci, P. M., Garagiola, I., El-Beshlawy, A., Elalfy, M., Ramanan, V., Eshghi, P., Hanagavadi, S., Varadarajan, R., Karimi, M., Manglani, M. V., Ross, C., Young, G., Seth, T., Apte, S., Nayak, D. M., Santagostino, E., Mancuso, M. E., Sandoval Gonzalez, A. C., ... Rosendaal, F. R. (2016). A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. New England Journal of Medicine, 374(21), 2054-2064. https://doi.org/10.1056/NEJMoa1516437

A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. / Peyvandi, F.; Mannucci, P. M.; Garagiola, I.; El-Beshlawy, A.; Elalfy, M.; Ramanan, V.; Eshghi, P.; Hanagavadi, S.; Varadarajan, R.; Karimi, M.; Manglani, M. V.; Ross, C.; Young, G.; Seth, T.; Apte, S.; Nayak, D. M.; Santagostino, E.; Mancuso, M. E.; Sandoval Gonzalez, A. C.; Mahlangu, J. N.; Bonanad Boix, S.; Cerqueira, M.; Ewing, N. P.; Male, C.; Owaidah, T.; Arellano, Soto V.; Kobrinsky, N. L.; Majumdar, S.; Perez Garrido, R.; Sachdeva, A.; Simpson, M.; Thomas, M.; Zanon, E.; Antmen, B.; Kavakli, K.; Manco-Johnson, M. J.; Martinez, M.; Marzouka, E.; Mazzucconi, M. G.; Neme, D.; Palomo Bravo, A.; Paredes Aguilera, R.; Prezotti, A.; Schmitt, K.; Wicklund, B. M.; Zulfikar, B.; Rosendaal, F. R.

In: New England Journal of Medicine, Vol. 374, No. 21, 26.05.2016, p. 2054-2064.

Research output: Contribution to journal › Article › peer-review

Peyvandi, F, Mannucci, PM, Garagiola, I, El-Beshlawy, A, Elalfy, M, Ramanan, V, Eshghi, P, Hanagavadi, S, Varadarajan, R, Karimi, M, Manglani, MV, Ross, C, Young, G, Seth, T, Apte, S, Nayak, DM, Santagostino, E , Mancuso, ME, Sandoval Gonzalez, AC, Mahlangu, JN, Bonanad Boix, S, Cerqueira, M, Ewing, NP, Male, C, Owaidah, T, Arellano, SV, Kobrinsky, NL, Majumdar, S, Perez Garrido, R, Sachdeva, A, Simpson, M, Thomas, M, Zanon, E, Antmen, B, Kavakli, K, Manco-Johnson, MJ, Martinez, M, Marzouka, E, Mazzucconi, MG, Neme, D, Palomo Bravo, A, Paredes Aguilera, R, Prezotti, A, Schmitt, K, Wicklund, BM, Zulfikar, B & Rosendaal, FR 2016, 'A randomized trial of factor VIII and neutralizing antibodies in hemophilia A', New England Journal of Medicine, vol. 374, no. 21, pp. 2054-2064. https://doi.org/10.1056/NEJMoa1516437

Peyvandi, F. ; Mannucci, P. M. ; Garagiola, I. ; El-Beshlawy, A. ; Elalfy, M. ; Ramanan, V. ; Eshghi, P. ; Hanagavadi, S. ; Varadarajan, R. ; Karimi, M. ; Manglani, M. V. ; Ross, C. ; Young, G. ; Seth, T. ; Apte, S. ; Nayak, D. M. ; Santagostino, E. ; Mancuso, M. E. ; Sandoval Gonzalez, A. C. ; Mahlangu, J. N. ; Bonanad Boix, S. ; Cerqueira, M. ; Ewing, N. P. ; Male, C. ; Owaidah, T. ; Arellano, Soto V. ; Kobrinsky, N. L. ; Majumdar, S. ; Perez Garrido, R. ; Sachdeva, A. ; Simpson, M. ; Thomas, M. ; Zanon, E. ; Antmen, B. ; Kavakli, K. ; Manco-Johnson, M. J. ; Martinez, M. ; Marzouka, E. ; Mazzucconi, M. G. ; Neme, D. ; Palomo Bravo, A. ; Paredes Aguilera, R. ; Prezotti, A. ; Schmitt, K. ; Wicklund, B. M. ; Zulfikar, B. ; Rosendaal, F. R. / A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. In: New England Journal of Medicine. 2016 ; Vol. 374, No. 21. pp. 2054-2064.

@article{d9b8c348f0224709a2f86380882ca987,

title = "A randomized trial of factor VIII and neutralizing antibodies in hemophilia A",

abstract = "BACKGROUND: The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age ",

author = "F. Peyvandi and Mannucci, {P. M.} and I. Garagiola and A. El-Beshlawy and M. Elalfy and V. Ramanan and P. Eshghi and S. Hanagavadi and R. Varadarajan and M. Karimi and Manglani, {M. V.} and C. Ross and G. Young and T. Seth and S. Apte and Nayak, {D. M.} and E. Santagostino and Mancuso, {M. E.} and {Sandoval Gonzalez}, {A. C.} and Mahlangu, {J. N.} and {Bonanad Boix}, S. and M. Cerqueira and Ewing, {N. P.} and C. Male and T. Owaidah and Arellano, {Soto V.} and Kobrinsky, {N. L.} and S. Majumdar and {Perez Garrido}, R. and A. Sachdeva and M. Simpson and M. Thomas and E. Zanon and B. Antmen and K. Kavakli and Manco-Johnson, {M. J.} and M. Martinez and E. Marzouka and Mazzucconi, {M. G.} and D. Neme and {Palomo Bravo}, A. and {Paredes Aguilera}, R. and A. Prezotti and K. Schmitt and Wicklund, {B. M.} and B. Zulfikar and Rosendaal, {F. R.}",

year = "2016",

month = may,

day = "26",

doi = "10.1056/NEJMoa1516437",

language = "English",

volume = "374",

pages = "2054--2064",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "21",

}

TY - JOUR

T1 - A randomized trial of factor VIII and neutralizing antibodies in hemophilia A

AU - Peyvandi, F.

AU - Mannucci, P. M.

AU - Garagiola, I.

AU - El-Beshlawy, A.

AU - Elalfy, M.

AU - Ramanan, V.

AU - Eshghi, P.

AU - Hanagavadi, S.

AU - Varadarajan, R.

AU - Karimi, M.

AU - Manglani, M. V.

AU - Ross, C.

AU - Young, G.

AU - Seth, T.

AU - Apte, S.

AU - Nayak, D. M.

AU - Santagostino, E.

AU - Mancuso, M. E.

AU - Sandoval Gonzalez, A. C.

AU - Mahlangu, J. N.

AU - Bonanad Boix, S.

AU - Cerqueira, M.

AU - Ewing, N. P.

AU - Male, C.

AU - Owaidah, T.

AU - Arellano, Soto V.

AU - Kobrinsky, N. L.

AU - Majumdar, S.

AU - Perez Garrido, R.

AU - Sachdeva, A.

AU - Simpson, M.

AU - Thomas, M.

AU - Zanon, E.

AU - Antmen, B.

AU - Kavakli, K.

AU - Manco-Johnson, M. J.

AU - Martinez, M.

AU - Marzouka, E.

AU - Mazzucconi, M. G.

AU - Neme, D.

AU - Palomo Bravo, A.

AU - Paredes Aguilera, R.

AU - Prezotti, A.

AU - Schmitt, K.

AU - Wicklund, B. M.

AU - Zulfikar, B.

AU - Rosendaal, F. R.

PY - 2016/5/26

Y1 - 2016/5/26

N2 - BACKGROUND: The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age

AB - BACKGROUND: The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS We conducted a randomized trial to assess the incidence of factor VIII inhibitors among patients treated with plasma-derived factor VIII containing von Willebrand factor or recombinant factor VIII. Patients who met the eligibility criteria (male sex, age

UR - http://www.scopus.com/inward/record.url?scp=84971222569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971222569&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1516437

DO - 10.1056/NEJMoa1516437

M3 - Article

C2 - 27223147

AN - SCOPUS:84971222569

VL - 374

SP - 2054

EP - 2064

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 21

ER -

A randomized trial of factor VIII and neutralizing antibodies in hemophilia A

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this